Alligator Bioscience AB

ATORX.STPhase 3

Lund, SwedenFounded 2001alligatorbioscience.com

Alligator Bioscience is dedicated to developing innovative antibody-based cancer immunotherapies. The company's core strategy revolves around its proprietary technology platforms designed to generate highly specific and potent antibodies. Its most advanced asset, mitazalimab (a CD40 agonist), is being evaluated in a pivotal Phase 2 trial for metastatic pancreatic cancer, a significant unmet medical need. The company also has a strategic partnership with Orion Corporation for the development of bispecific antibodies and collaborates with other biopharmaceutical firms.

Market Cap

$10.3M

Founded

2001

Employees

50-100

Focus

Biotech

ATORX.ST · Stock Price

USD 0.18102.82 (-99.83%)

Historical price data

AI Company Overview

Technology Platform

Proprietary antibody discovery platforms including ALiCE® (for generating fully human antibodies against membrane proteins) and RUBY™ (for generating tumor-selective bispecific T-cell engagers).

Pipeline Snapshot

7 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
mFOLFOX regimen + Mitazalimab	Biliary Tract Cancer (BTC)	Phase 2/3
CD40 agonist mitazalimab in combination with chemotherapy	Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1/2
ALG.APV-527	Solid Tumor	Phase 1/2
ATOR-1015	Solid Tumor	Phase 1
ATOR-1017	Solid Tumor	Phase 1

Funding History

Total raised: $36.6M

PIPE$8.5MUndisclosedJun 15, 2023

Debt$10MSwedbankSep 15, 2021

Grant$2.5MVinnovaMar 15, 2020

IPO$15.6MUndisclosedNov 18, 2016

Opportunities

Positive data from the pivotal Phase 2 trial of mitazalimab in pancreatic cancer could unlock significant value and lead to partnerships or M&A.

The RUBY™ bispecific platform offers opportunities to generate new drug candidates for internal development or out-licensing deals in the high-value T-cell engager space.

Risk Factors

High dependency on the success of a single clinical asset (mitazalimab) in a challenging indication.

Pre-revenue status necessitates future dilutive capital raises.

Intense competition in the immuno-oncology space from larger, better-funded companies.

Competitive Landscape

Competes in the CD40 agonist space with companies like Apexigen and Roche. Its bispecific platform competes with numerous established players like Amgen and Regeneron. Differentiation is based on mitazalimab's specific Fc-engineering and the tumor-selective design of the RUBY™ platform.